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Abstract
Background: Mycobacterium africanum comprises two phylogenetic lineages within the M. tuberculosis complex
(MTBC) and is an important cause of human tuberculosis (TB) in West Africa. The reasons for this geographic
restriction of M. africanum remain unclear. Here, we performed a prospective study to explore associations between
the characteristics of TB patients and the MTBC lineages circulating in Ghana.
Method: We genotyped 1,211 MTBC isolates recovered from pulmonary TB patients recruited between 2012 and
2014 using single nucleotide polymorphism typing and spoligotyping. Associations between patient and pathogen
variables were assessed using univariate and multivariate logistic regression.
Results: Of the 1,211 MTBC isolates analysed, 71.9 % (871) belonged to Lineage 4; 12.6 % (152) to Lineage 5 (also
known as M. africanum West-Africa 1), 9.2 % (112) to Lineage 6 (also known as M. africanum West-Africa 2) and 0.
6 % (7) to Mycobacterium bovis. Univariate analysis revealed that Lineage 6 strains were less likely to be isoniazid
resistant compared to other strains (odds ratio = 0.25, 95 % confidence interval (CI): 0.05–0.77, P < 0.01). Multivariate
analysis showed that Lineage 5 was significantly more common in patients from the Ewe ethnic group (adjusted
odds ratio (adjOR): 2.79; 95 % CI: 1.47–5.29, P < 0.001) and Lineage 6 more likely to be found among HIV-co-infected
TB patients (adjOR = 2.2; 95 % confidence interval (CI: 1.32–3.7, P < 0.001).
Conclusion: Our findings confirm the importance of M. africanum in Ghana and highlight the need to differentiate
between Lineage 5 and Lineage 6, as these lineages differ in associated patient variables.
Background
Tuberculosis (TB) remains one of the main global public
health problems, particularly in resource-limited settings
[1]. With an estimated 9 million new cases annually, and
a pool of two billion latently infected individuals, control
efforts are struggling in most parts of the world. The TB
problem is further exacerbated by a strong synergy with
Human immunodeficiency virus infection and acquired
immune deficiency syndrome (HIV/AIDS), which is a par-
ticularly big challenge in sub-Saharan Africa. Moreover,
the global emergence of drug resistance increasingly com-
plicates TB control. The Word Health Organization
(WHO) estimates that in 2013, of the 1.1 million TB cases
co-infected with HIV, 80 % occurred in Africa, making
Africa the hardest hit of the two epidemics [1].
Human TB is mainly caused by Mycobacterium africa-
num (MAF) and Mycobacterium tuberculosis sensu
stricto (MTB), both members of Mycobacterium tuber-
culosis complex (MTBC), which also includes several
sub-species adapted to a variety of wild and domestic
animals [2, 3]. MAF first identified in 1968 in Senegal,
was initially described biochemically as an intermediary
between MTB and M. bovis [4]. Like MTB, MAF strains
were found to be sensitive to pyrazinamide; like M.
bovis, they tended to be a weak producer of niacin,
microaerophilic, and unable to reduce nitrate to nitrite
[5]. Furthermore, similar to M. bovis they are unable to
use glycerol as a sole carbon source due to the lack of
functional pyruvate kinase [6]. Initial biochemical fea-
tures subdivided MAF into two separate groups; the
West-African sub-species and East-African also referred
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to as MAF type 1 and 2 [7]. However, based on genomic
deletion analyses [2, 8, 9], we now know that MAF type
2 variant is a sub-lineage of MTB Lineage 4, which has
been reclassified as MTB “Uganda sublineage” [10].
MAF type 1 or the “true” M. africanum consists of two
phylogenetically distinct lineages that differ in their geo-
graphic distribution: Lineage 5 (also known as MAF
West African 1) is found in the eastern part of West-
Africa, and Lineage 6 (also known as West-Africa geno-
type II) is mainly found in the western part of West-
Africa. A few countries like Ghana and Cote d’Ivoire
harbor both Lineages 5 and 6 [9, 11].
The reason why MAF is largely restricted to the West
African region remains unknown, but one possibility
might be that MAF is adapted to distinct human popula-
tion (s) in West Africa [9]. In support of this hypothesis,
using a limited retrospective collection of MTBC isolates
from South-western Ghana, we recently reported an as-
sociation between MAF and the Ewe ethnic group [12].
One of the limitations of that previous study was that
due to lack of relevant data, we could not control for
possible confounding by HIV co-infection. Hence, we
followed-up on this initial observation with a larger
population-based prospective study in which we in-
cluded more detailed clinical data and TB cases from
both the southern and northern part of Ghana.
Methods
Ethical Statement and Patient inclusion criteria
The Institutional Review Board of the Noguchi Memorial
Institute for Medical Research (NMIMR) and the Ethik-
kommission Beider Basel (EKBB) in Basel, Switzerland ap-
proved the study and its protocols. Following informed
consent, consecutive sputum smear-positive TB cases
were recruited from September 2012 to April 2014 from
all TB diagnostic centres in the Accra Metropolitan
(Southern) and the Mamprusi East (Northern Region)
Health Administrations. The standard procedure for
sputum sample collection as outlined by the National
Tuberculosis Program (NTP) for routine diagnosis of TB
in Ghana was used in this study. Participants provided
written consent unless the participant was illiterate; in
which case witnessed oral consent was used. In accord-
ance with ethical review board regulation in Ghana con-
sent was sought from guardians of children below the age
of 18 before enrolment into the study and in some cases
child assent was also sought. Samples were taken only
after a detailed explanation of the study aims and written
or thumb-printed consent obtained for participation. Only
newly diagnosed smear-positive, pulmonary TB patients
before initiation of treatment or less than 4 weeks of treat-
ment were enrolled into the study. All eligible TB patients
were encouraged to undergo HIV testing before initiation
of anti-TB treatment according to national guidelines.
Data collected from enrolled patients included age, sex,
immunosuppressive co-morbidity with HIV, place of
work, previous episode of TB, housing type, place of resi-
dence, ethnicity, smoking, level of education, income, and
presence of Bacillus Calmette-Guerin (BCG) scar. All pa-
tients and staff involved with the study were blinded to
the final data obtained and none of the authors have a
conflict of interest in the study.
Laboratory tests
The sputum samples were re-examined for the presence
of acid-fast bacilli (AFBs) at NMIMR and cultured on
solid agar, after which isolate deoxyribonucleic acid
(DNA) was extracted for genotyping analysis. Briefly, we
took a 10 μL loop full from a Lowenstein-Jensen medium
slope and, after heat killing, extracted DNA first by diges-
tion with lysozyme and proteinase K, solubilized by deter-
gents sodium dodecyl sulphate and cetrimonium bromide,
followed by chloroform isopropanol extraction [13].
Genotyping of MTBC isolates
Classification of mycobacterial isolates into the main
phylogenetic lineages within the MTBC were by TaqMan
real-time PCR (TaqMan, Applied Bio systems, USA)
using probes targeting lineage-specific SNPs as reported
by Stucki et al. [14]. Spoligotyping was performed to de-
fine the sub-lineages and strain families within each of
the main lineages circulating in Ghana [15]. Spoligotyp-
ing patterns were defined according to SITVITWEB
database [16] (http://www.pasteur-guadeloupe.fr: 8081/
SITVIT_ONLINE). SITVITWEB assigned shared types
numbers were used whenever a Spoligotyping pattern
was found in the database while families and subfamilies
were assigned based on the MIRU-VNTRplus database
(http: //www. miru-vntrplus.org) [17].
Anti-TB Drug Susceptibility Testing
All MTBC isolates were screened for their susceptibility
to isoniazid (INH) and Rifampicin (RIF) using the Geno-
type MTBDRplus (Hain lifescience), according to the
manufacturer’s protocol [18]. Briefly, drug resistance was
expressed as the absence of wild-type band, presence of
mutation band or both.
Data entry, management and analysis
Information from the structured questionnaire was
double entered using Microsoft Access and validated to
remove duplicates and data entry inconsistencies. Spoli-
gotype patterns were entered in a binary format. A series
of univariate and multivariable logistic regression models
were fitted to assess the relationship between MTBC
lineage (s) (primary independent variable) and host vari-
ables. For the MTBDRplus assay, definition of specific
drug resistance was based on mutations within the katG
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gene and inhA promoter for INH and rifampicin resist-
ance determining region of the rpoB gene for RIF. This
was captured as either absence of specific wild-type band
and/or presence of mutation band corresponding to spe-
cific mutations.
Results
Patient characteristics
From September 2012 to April 2014, 1,330 smear-
positive TB cases recruited from various diagnostic la-
boratories in the Greater Accra Region and the Northern
Region of Ghana were enrolled into the study. We ex-
cluded 80 cases from further analysis because no MTBC
cultures were obtained from their sputa. A further 30
strains identified as non-tuberculous mycobacteria and 9
strains which produced ambiguous genotyping results
were excluded, leaving 1,211 unique MTBC patient iso-
lates for further analyses.
A summary of characteristics of the study population
is provided in Table 1. The median age of patients was
39 years (range 3 to 91 years). Thirty-one percent (373/
1,211) were females with median age of 33 years; the
remaining 838 (69 %) were males with a median age of
36. Only 2.3 % (28/1,211) were children (age < 16 years).
Most of the patients (N = 1,112; 91.8 %) were recruited
from the southern part of Ghana with the remaining 99
(8.2 %) from northern Ghana. Most patients (N = 1,160,
95.8 %) were Ghanaians with the remaining 51 (4.2 %) of
other West African nationalities. Participants were pre-
dominantly of the Akan ethnicity (N = 604, 49.9 %),
followed by Ga (N = 280, 23.1 %), Ewe (N = 184, 15.2 %)
with the remaining ethnicities (N = 143) accounted for
11.8 %. Majority of participants (N = 766, 63.3 %) had
formal education level of secondary education or lower
whilst 346 patients (28.6 %) had no formal education.
More than half of our study population (N = 591,
48.8 %) were unskilled labourers, 314 skilled (26 %) with
the remaining 306 (25.2 %) unemployed. Most of the
study participants harbored a high bacterial burden as
measured by sputum smear microscopy; 3+ (N = 534,
44.1 %), followed by 2+ (N = 295, 24.4 %), 1+ (N = 266,
22 %) and scanty (N = 115, 9.5 %). All 1,211 TB patients
consented to HIV testing, and among them, 160
(13.2 %) were HIV sero-positive.
The population structure of the MTBC in Ghana
SNP-typing identified 871 (71.9 %) isolates as Lineage 4
(also known as the Euro American lineage), 152 isolates
(12.6 %) as Lineage 5, 112 isolates (9.2 %) as Lineage 6,
15 isolates (1.2 %) as Lineage 1, 42 isolates (3.5 %) as
Lineage 2, 12 isolates (1 %) as Lineage 3, and 7 (0.6 %)
as M. bovis (Additional file 1: Table S1). Among the 871
Lineage 4 isolates, spoligotyping revealed that 503/871
(58 %) belonged to the ‘Cameroon family’, the most
dominant sub-lineage of Lineage 4 in Ghana, with the
most prevalent spoligotype 61 accounting for 349
(40.1 %) isolates. Seventy–three percent of strains
Table 1 Characteristics of patients included in the study
Variable N (Total = 1211) %
Sex
Male 838 69.0
Female 373 31.0
Age category
yr 08–25 227 18.7
yr 26–40 496 41.0
yr 41–77 488 40.3
Residency
North 99 8.2
South 1112 91.8
Occupation
Unskilled 591 48.8
Skilled 314 26.0
Unemployed 306 25.2
Nationality
Ghanaian 1160 95.8
West Africans 51 4.2
Income (GHC)
None 449 37.1
<100 184 15.2
100–500 505 41.7
>500 73 6.0
Smear positivity
Scanty 1–9 115 9.5
+1 266 22.0
+2 295 24.4
+3 534 44.1
Ethnicity
Akan 604 49.9
Ewe 184 15.2
Ga 280 23.1
other 143 11.8
HIV status
Positive 160 13.2
Education
No Education 346 28.6
Primary 134 11.1
Secondary 632 52.2
Tertiary 99 8.2
Presence of BCG Scar
Yes 505 41.7
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isolated from other West African nationals (37/51)
belonged to the ‘Cameroon family’.
In addition to the Cameroon family, seven other sub-
lineages were identified among Lineage 4 based on spoli-
gotyping; Ghana (N = 198/871, 22.7 %), Haarlem (N = 83,
9.5 %), Uganda I (N = 27, 3.0 %), LAM (N = 26, 2.9 %),
Uganda II (N = 2, 0.2 %), S (N = 2 (0.2 %), New_1 (N = 1,
0.1 %) and H37Rv_like (N = 1, 0.1 %).
Spoligotyping of the 264 MAF (Lineage 5 and 6 com-
bined) isolates revealed 92 distinct spoligotypes patterns.
Fifty-two unique patterns (singletons) were observed
with the remaining 40 patterns grouped into clusters of
2–26 isolates respectively (Additional file 1: Table S1).
Within the 940 MTB isolates, we had 101 patterns,
consisting of 60 patterns grouped into clusters of 2–349
isolates respectively, 19 singletons and remaining 11 iso-
lates identified as orphans. We compared the 193 spoli-
gotypes found in this study with those contained in an
international spoligotype database, 130 of our spoligo-
types were already described in SITVIT database. The
other 63 spoligotypes were novel.
Prevalence of drug resistance among the main MTBC
lineages
After excluding the 7M. bovis isolates, all remaining 1,204
isolates were analysed by GenoType® MTBDRplus using
mutations as specified by manufacturer (Additional file 2:
Table S2). Overall, MTBDRplus identified 90/1,204
(7.5 %), 7/1,204 (0.6 %) and 21/1,211 (1.7 %) of the isolates
as INH-mono-resistant, RIF mono-resistant and MDR, re-
spectively (Table 2). Among our data set, the number of
isolates belonging to the Lineages 1–3 was limited. There-
fore, for the remaining analyses, we compared Lineage 5
(N = 152) and Lineage 6 (N = 112) with all the other MTB
lineages combined (N = 940, Lineages 1–4). Based on uni-
variate analysis, we did not find any association between
MDR and Lineage 5 compared to Lineages 1–4 (OR 1.1,
95 % CI: 0.6–2.0), but Lineage 6 was four times less likely
to harbour any form of INH resistance (OR = 0.25 95 %
CI: 0.05–0.77, Fischer’s Exact test P < 0.01). All the RIF
mono-resistant isolates (N = 7) belonged to Lineage 4.
MTBC lineage associations with patient characteristics
Further univariate analyses revealed that Lineage 5 was
significantly associated with Ewe ethnicity (OR = 3.0,
95 % CI: 1.5–4.7) (Table 3). Similarly, Lineage 6 was sig-
nificantly associated with HIV co-infection (OR = 2.4,
95 % CI: 1.4–3.9). Both of these associations remained
statistically significant after adjusting for age and gender
using multivariate logistic modeling, (adjusted odds ratio
(adjOR) =2.79, 95 % CI: 1.47–5.29, and adjOR = 2.2,
95 % CI: 1.32–3.7, respectively). No other significant as-
sociation was found between MTBC lineage and other
patient variables, including age, income, sex, the pres-
ence of a BCG scar, or the degree of smear positivity.
Discussion and conclusions
Our molecular epidemiological analysis revealed that i)
MAF remains an important pathogen in Ghana, causing
one fifth of all human TB cases in Ghana, ii) TB patients
of the Ewe ethnicity were more likely to be infected with
Lineage 5, and iii) Lineage 6 isolates were less likely to
be INH-resistant and more frequent in TB patients co-
infected with HIV.
The observation that MAF remains an important
cause of pulmonary TB in Ghana is in contrast to the
decline of MAF that has been reported in Cameroon
[19]. In that country, MAF might gradually being out-
competed by more virulent MTB. In support for this hy-
pothesis, MAF has been associated with reduced viru-
lence in animal models [4], and a longer latency and a
slower rate of progression to active disease in humans
[9]. The reason for the persistence of MAF in Ghana
over time is unclear but might be partially related to our
previous finding that MAF is associated with the Ewe
ethnic group [12]. Lineage 5, a finding that we replicated
in the present study, drove this association. While we
were not able to control for HIV infection in our previ-
ous study, in the present study, the patient HIV status
was available and included in the analysis. Yet despite
this potential confounding factor, the association be-
tween Lineage 5 and Ewe ethnicity remained significant.
Based on these findings, we hypothesize that Lineage 5
is particularly well adapted to infect and cause TB in the
Ewe population [12].
This hypothesis follows on an increasing body of evi-
dence indicating that different MTBC genotypes might be
adapted to different human populations [20–23]. More-
over, several studies have reported interactions between
host and pathogen genotypes in human TB [22–24]. For
example, a study in Vietnam found an association between
the T597C allele of the Toll-like receptor 2 gene (TLR2)
and infection by Lineage 2 [25]. Similarly, studies per-
formed in Ghana have reported human polymorphism in
5-lipoxygenase (ALOX5) [26] and Mannose Binding Lec-
tin (MBL) which gives protection to TB caused by either
MAF or MTB [27]. Most recently, a study in South Africa
reported on the association between different HLA class I
types and disease caused by different MTBC strain
Table 2 Prevalence of drug resistance among the main MTBC
lineages
Drug
Resistance
Lineage (Number of Isolates)
Lineage 4 (940) Lineage 5 (152) Lineage 6 (112)
INHmono 74 (7.9 %) 14 (7.9 %) 2 (3.6 %)
RIFmono 7 (0.7 %) 0 (0.0 %) 0 (0.0 %)
MDR 15 (1.6 %) 6 (3.3 %) 0 (0.0 %)
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Table 3 Distribution of patient variables across the three main MTBC lineages in Ghana
Risk factor MAF Lineage 5
(N = 152)
MAF Lineage 6
(N = 112)
MTB (Lineages
1–4) (N = 940)
OR (95 % CI)
(Lineage 5 vs. 1–4)
adjOR (95 % CI)a
(Lineage 5 vs 1–4)
OR (95 % CI)
(Lineage 6 vs 1–4)
adjOR (95 % CI)a
(Lineage 6 vs 1–4)
N (% N (% N (%
Sex
Male 96 (63.2) 73 (65.2) 662 (70.6) 1.3 (0.97–1.98)
Female 56 (36.8) 39 (34.8) 278 (29.4)
Age category
yr 08–25 28 (18.0) 17 (15.2) 181 (19.4) 1.42 (0.82–2.64)
yr 26–40 62 (41.0) 49 (43.8) 383 (40.6) 0.96 (0.4–1.96)
yr 41–77 62 (41.0) 46 (41.0) 376 (40.0) 1.06 (0.59–1.91)
Residency
North 8 (5.3) 8 (7.1) 82 (9.0) 0.58 (0.27–1.22)
South 144 (94.7) 104 (92.2) 858 (91.0) ref
Occupation
Skilled 35 (23.0) 24 (21.4) 171 (27.2) 0.9 (0.81–1.0)
Unskilled 117 (77.0) 88 (78.6) 769 (72.8) ref
Income (GHC)
None 65 (42.7) 43 (38.4) 260 (47.3) 0.8 (0.62–0.98)*
<100 32 (21.1) 16 (14.3) 136 (14.5) 0.91 (0.76–1.0)
100–500 51 (33.5) 45 (40.2) 408 (32.3) ref
>500 4 (2.6) 8 (7.1) 58 (5.9) 1.3 (0.97–1.98)
Smear positivity
Scanty 1–9 2 (1.3) 0 80 (9.2) 0.6 (0.45–0.72)*
+1 34 (22.6) 18 (16.1) 199 (22.8) 0.78 (0.65–1.80)
+2 37 (24.3) 28 (25.0) 213 (24.6) 0.98 (0.42–1.84)
+3 79 (52.0) 66 (58.9) 352 (40.4) ref
Ethnicity
Akan 39 (25.7) 78 (69.7) 482 (51.4) ref
Ewe 58 (38.2) 10 (8.9) 116 (12.6) 3.0 (1.5–4.70) 2.79 (1.47–5.29)**
Ga 47 (30.9) 11 (9.8) 221 (22.6) 0.85 (0.43–1.69)
Other 8 (5.3) 13 (11.6) 118 (13.3) 1.64 (0.53–5.34)
HIV status
Positive 28 (29.5) 29 (34.9) 96 (18.5) 2.4 (1.4–3.90)* 2.2 (1.32–3.70)*
Education
No Education 50 (32.9) 40 (35.7) 231 (26.5) 0.83 (0.75–1.0)
Primary 21 (13.8) 15 (13.4) 91 (10.4) 0.72 (0.65–1.11)
Secondary 70 (46.1) 47 (42.0) 477 (54.8) 0.96 (0.83–1.30)
Tertiary 11 (7.2) 10 (8.9) 72 (8.3)
BCG Scar
Present 64 (42.1) 46 (41.1) 430 (41.4) 1.1 (0.69–1.7)
Smoking
Yes 25 (16.4) 28 (25.0) 248 (20.6) 0.6 (0.7–1.8)
aAll variables with an OR above 1.5 or below 2/3 were included in the multivariable model, *P < 0.05, **P < 0.001, MAF =Mycobacterium africanum
MTB mycobacterium tuberculosis sensu stricto
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families in a South African indigenous population [28].
More studies are needed to confirm the hypothesis that
the genetic background of Ewe populations is particularly
conducive to infection and disease caused by Lineage 5
and to identify the biological processes involved in this
interaction.
Even if the association between Lineage 5 and Ewe
ethnicity is contributing to the stable prevalence of MAF
in Ghana over time, about half of all MAF cases are due
to Lineage 6, which is phylogenetically distinct from
Lineage 5 [29]. The findings reported here indicate that
Lineage 5 and Lineage 6 also differ phenotypically with
respect to their associations with particular patient vari-
ables. We found that Lineage 6 was less likely to show
any form of INH resistance. This is consistent with re-
ports from Mali that found Lineage 6 less likely to be
multidrug-resistant compared to other MTBC lineages
[30]. Drug resistance in many bacteria, including MTBC
is often associated with a fitness cost [31]. Hence, the
fact that Lineage 6 is already attenuated compared to
other MTBC lineages [9, 32] might limit its potential for
drug resistance acquisition. In support of this idea,
Lineage 6 has been associated with inhA promoter mu-
tations conferring low levels of resistance to isoniazid
that have no known impact on bacterial fitness [33]. In
contrast, most other MTBC strains tend to harbour mu-
tations in katG conferring high levels of resistance, some
of which are associated with a high fitness cost [34].
The relative attenuation of Lineage 6 has led to the hy-
pothesis that this lineage might be an opportunistic
pathogen [35]. This view is supported by the findings re-
ported here, as well as previous work by others [9]
showing an association between Lineage 6 and HIV co-
infection [34]. A previous study from Ghana found no
such association, perhaps reflecting differences in study
design [36]. Moreover, de Jong et al. reported that
Lineage 6 was significantly more frequent in elderly TB
patients, consistent with both slower progression to ac-
tive disease [37] and the role of age-related immunosup-
pression [34]. Recent advances in phylogenomics of the
MTBC show that even though Lineage 6 has primarily
been isolated from humans, it is phylogenetically most
closely related to several animal-adapted variants of the
MTBC [24] including the recently discovered chimpan-
zee bacillus [38] as well as M. suricattae and M. mungi
which cause TB-like disease in meerkats and banded
mangooses, respectively [39]. The potential for an un-
known animal reservoir for Lineage 6 has been discussed
for some time but so far, none has been discovered [9].
Moreover, unlike other animal-adapted members of the
MTBC that rarely cause TB in humans and cannot
maintain a full life cycle in human populations [40],
Lineage 6 transmits readily among humans [9]. So far,
the role of HIV in driving Lineage 6 remains unclear.
Even though HIV had a dramatic impact on the TB epi-
demic in Sub-Saharan Africa, Lineage 6 remains re-
stricted to the Western part of the continent, which
shows much lower rates of HIV infection compared to
Southern Africa. Hence, other factors are likely to deter-
mine to epidemiology of Lineage 6.
In conclusion, our study confirms that MAF remains an
important cause of human TB in Ghana. Our findings also
emphasize the need to differentiate between Lineage 5
and 6, and show that the differences between these line-
ages are relevant for understanding the phylogeography of
MAF; while human genetic factors may drive Lineage 5,
unknown environmental factors seem to influence the epi-
demiology of Lineage 6. More generally, these results also
highlight the current problems with the species nomencla-
ture in the MTBC [39]. Indeed, the phylogenetic, pheno-
typic, and ecological differences between Lineage 5 and
Lineage 6 argue against them being collectively referred to
as MAF, as opposed to just separate lineages within MTB.
Finally, given the current efforts in the development of
new TB vaccines, our findings also highlight the need to
consider the MTBC variability in the development of new
tools and strategies to control TB especially in area where
Lineages 5 and 6 are prevalent.
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